Meeting Banner
Abstract #3418

Pre-Therapy Ferumoxytol-Enhanced Magnetic Resonance Imaging (MRI) Predicts Response of Metastatic Breast Cancer to Liposomal Irinotecan

Harshan Ravi1, Andres M. Arias Lorza1, James R. Costello2, Hyo Sook Han3, Daniel K. Jeong2, Stephan G. Klinz Klinz4, Jasgit C. Sachdev5, Ronald L. Korn6, and Natarajan Raghunand1,7
1Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa,, FL, United States, 2Department of Radiology, Moffitt Cancer Center and Research Institute, Tampa,, FL, United States, 3Department of Breast Oncology, Moffitt Cancer Center and Research Institute, Tampa,, FL, United States, 4Ipsen Bioscience, Cambridge, MA, United States, 5HonorHealth Research Institute, Scottsdale, AZ, United States, 6Imaging Endpoints Core Lab, Scottsdale, AZ, United States, 7Department of Oncologic Sciences, University of South Florida, Tampa,, FL, United States

Synopsis

R*2 and the apparent concentration of FMX in the tumor (FMXC) are considered biomarkers of liposomal irinotecan (nal-IRI) drug uptake into that tumor lesion, which in turn would determine response of that tumor to nal-IRI. Historically, quantification of R*2 and FMXC had been implemented by using a calibration phantom and acquiring patient scans both pre-FMX and post-FMX. Here we have demonstrated a pre-treatment FMX-enhanced MRI companion biomarker of response to nal-IRI in mBC patients that can be computed from a single16-24 h post-FMX MRI scan without the need for calibration phantoms or pre-FMX scans.

This abstract and the presentation materials are available to members only; a login is required.

Join Here